Insmed (NASDAQ:INSM) CEO William Lewis Sells 7,605 Shares

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 7,605 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $777,763.35. Following the completion of the sale, the chief executive officer owned 265,432 shares in the company, valued at $27,145,730.64. This trade represents a 2.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

William Lewis also recently made the following trade(s):

• On Thursday, April 16th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $143.97, for a total value of $1,540,335.03.
• On Monday, April 6th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $163.22, for a total value of $1,746,290.78.
• On Thursday, March 19th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $143.52, for a total value of $1,535,520.48.

Insmed Trading Down 10.2%

NASDAQ INSM opened at $94.22 on Friday. The business’s 50-day moving average price is $130.45 and its two-hundred day moving average price is $154.95. Insmed, Inc. has a 12 month low of $70.57 and a 12 month high of $212.75. The firm has a market capitalization of $20.42 billion, a PE ratio of -16.39 and a beta of 0.79. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The firm had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. During the same quarter in the previous year, the company posted ($1.42) EPS. The business’s revenue was up 229.7% on a year-over-year basis. On average, analysts expect that Insmed, Inc. will post -2.56 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in INSM. EverSource Wealth Advisors LLC raised its stake in Insmed by 65.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 263 shares during the period. First Trust Advisors LP raised its stake in Insmed by 80.8% during the 2nd quarter. First Trust Advisors LP now owns 47,392 shares of the biopharmaceutical company’s stock worth $4,770,000 after buying an additional 21,176 shares during the period. Baird Financial Group Inc. acquired a new position in Insmed during the 2nd quarter worth approximately $2,589,000. Amundi raised its stake in Insmed by 21,194.4% during the 2nd quarter. Amundi now owns 11,499 shares of the biopharmaceutical company’s stock worth $1,130,000 after buying an additional 11,445 shares during the period. Finally, Natixis acquired a new position in Insmed during the 2nd quarter worth approximately $1,072,000.

Analysts Set New Price Targets

INSM has been the topic of a number of analyst reports. Jefferies Financial Group initiated coverage on Insmed in a research report on Monday, March 16th. They issued a “buy” rating and a $228.00 price target on the stock. Roth Mkm reiterated a “buy” rating and issued a $212.00 price target on shares of Insmed in a research report on Friday, April 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a research report on Tuesday, April 21st. Truist Financial reduced their price target on Insmed from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Finally, Wells Fargo & Company cut their target price on Insmed from $177.00 to $160.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Insmed has an average rating of “Moderate Buy” and an average price target of $210.50.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.